Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Mechanisms influencing mitochondrial dysfunction in Alzheimer’s disease

Mounia Chami, PhD-HDR, Institute of Molecular and Cellular Pharmacology (IPMC), Sophia-Antipolis, France, discusses signaling cascades that could be linked to mitochondrial dysfunction in Alzheimer’s disease (AD). Mitochondrial dysfunction is common across many neurodegenerative disorders, especially in AD. Asides from targeting the AMPK cascade, the accumulation of amyloid precursors and the modulation of amyloid precursor protein (APP) processing are key pharmacological targets across many laboratories. Dr Chami further discusses the possibility of enhancing mitochondrial function and directly targeting mitophagy defects. Finding a balance between functional mitochondria and the elimination of dysfunctional mitochondria is a prosperous avenue to follow in the therapeutics of AD. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.